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Despite the increasing understanding of female reproduction, the molecular diagnosis of primary ovarian insufficiency (POI) is
seldom obtained. The RNA-binding protein NANOS3 poses as an interesting candidate gene for POI since members of the Nanos
family have an evolutionarily conserved function in germ cell development andmaintenance by repressing apoptosis.Weperformed
mutational analysis of NANOS3 in a cohort of 85 Brazilian women with familial or isolated POI, presenting with primary or
secondary amenorrhea, and in ethnically-matched control women.Ahomozygous p.Glu120Lysmutation inNANOS3was identified
in two sisters with primary amenorrhea.The substituted amino acid is located within the second C2HCmotif in the conserved zinc
finger domain ofNANOS3 and in silicomolecularmodelling suggests destabilization of protein-RNA interaction. In vitro analyses of
apoptosis through flow cytometry and confocal microscopy show that NANOS3 capacity to prevent apoptosis was impaired by this
mutation. The identification of an inactivating missense mutation in NANOS3 suggests a mechanism for POI involving increased
primordial germ cells (PGCs) apoptosis during embryonic cell migration and highlights the importance of NANOS proteins in
human ovarian biology.
1. Introduction
Primary ovarian insufficiency (POI) is characterized by
ovarian failure in women under the age of 40 years [1, 2].
POI may present as primary amenorrhea (PA) in severe cases
with prepubertal onset or postpubertally as secondary amen-
orrhea (SA) associated with infertility, hypoestrogenism, and
elevated gonadotropins (FSH > 40U/L). This complex spec-
trum of progressive ovarian abnormality is largely related
to the size of primordial germ cells (PGCs) pool, where
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prepubertal onset might reflect a complete lack of germ
cells since birth causing a failure in the maintenance of
ovarian somatic structure and postpubertal onset would
reflect a variably insufficient pool of oocytes. This disorder
is associated with female infertility and affects 1 to 2% of all
women [3–5].
Several genetic mechanisms may lead to POI, including
chromosomal abnormalities of the X chromosome or auto-
somes and autoimmune disorders [6]. Despite the increas-
ing understanding of female reproduction, defined causes
or mechanisms resulting in primary ovarian insufficiency
remain largely unknown [7]. Persani et al. have estimated the
prevalence of known genetic alterations in POI patients orig-
inally classified as idiopathic to be around 20 to 25% of cases
[8], whereas others have found this prevalence to be lower,
around 10%. Rare mutations have been described in genes
involved in ovarian development and/or function such as
FSHR (MIM 136435), LHCGR (MIM 152790), BMP15 (MIM
300247), POF1B (MIM 300603), NOBOX (MIM 610934),
INHA (MIM 147380), GDF9 (MIM 601918), NR5A1 (MIM
184757), and FIGLA (MIM 608697) and in meiotic genes
[9–23]. Nevertheless, mutations in these genes account for
a minority of cases of ovarian dysfunction, indicating that
additional factors remain to be identified.
Nanoswas first identified inDrosophila, where it represses
the translation of target mRNAs through binding to their 3󸀠
UTR and has a conserved function in germ cell development
across species. Members of the evolutionarily conserved
Nanos gene family are preferentially expressed in the ovaries
and are known to play an important role in germ cell devel-
opment, maintenance, and survival [24–30]. In Drosophila,
the single Nanos gene (Nos) is required for development of
the abdomen as well as for germ line maintenance [31, 32].
Three Nanos homologues exist in mouse, with Nanos2 and
Nanos3 functioning primarily inmale germ cell development
andmaintaining PGCs viability, respectively [33, 34]. Inmice,
Nanos3 is expressed in the primordial germ cells (PGCs) from
their formation until shortly after their appearance in the
gonads (E13.5 in female and E14.5 in male embryos) [24].
Male and female mice deficient in Nanos3 are infertile, and
female 𝑁𝑎𝑛𝑜𝑠3−/− mice have atrophic ovaries in which no
germcells are detectable due to loss ofmigrating PGCsduring
embryogenesis [24]. PGCs are lost by apoptosis in the absence
of Nanos3, establishing an essential function of Nanos3 as a
repressor of apoptosis in the germ cell [34].
A similar conserved function for NANOS proteins has
been shown in humans. NANOS1 and NANOS2 seem to
be mainly involved with male germ cell development and
maintenance [35], and indeed NANOS1 mutations have been
associated with male infertility manifested as nonobstructive
azoospermia or oligozoospermia [36].NANOS3, on the other
hand, is expressed in both male and female fetal and adult
gonads, and in vitro evidence suggests a pivotal function in
human germ cell development [37].
Despite this compelling evidence for the importance of
NANOS3 in germ cell maintenance, initial efforts to identify
NANOS3mutations in women with POI were not successful:
in 2007, Qin et al. analyzed 168 infertile Caucasian and
Chinese women and failed to identify pathogenic mutations
[38]. More recently, however,Wu et al. performedmutational
analysis of the coding regions of NANOS1, NANOS2, and
NANOS3 in 100 Chinese POI patients, identifying a het-
erozygous p.Arg153Trp NANOS3 mutation in a 23-year-old
woman [39].ThemutantNANOS3 proteinwas shown to have
decreased stability in vitro, leading the authors to postulate
that reduced expression of NANOS3 in the ovaries would
result in decreased PGC population and POI [39]. Herein we
report a homozygous missense mutation in Nanos3 found in
two sisters from our cohort of 85 Brazilian women with POI
and present supporting in vitro functional data.
2. Materials and Methods
2.1. Subjects. This study was approved by the ethics commit-
tee of Hospital das Clinicas, University of Sao Paulo School of
Medicine, Brazil (Protocol number 1226/07).
Eighty-five patients with POI were referred to the Devel-
opmental Endocrinology Unit of Hospital das Clinicas, Sao
Paulo, or to the Pediatric Department of University of
Campinas, in Sao Paulo, Brazil, for evaluation of primary
amenorrhea (45 patients, 10 familial cases) or secondary
amenorrhea (40 unrelated patients). The age at diagnosis
of amenorrhea was 29.2 ± 5.9 years (18 to 39 yrs). Parental
consanguinity was present in 80% of familial cases, and no
other relevant familial history was reported. Each family had
2 affected individuals, and age at diagnosis of familial cases
was 19.4 ± 6.2 years (14 to 36 yrs). FSH levels were elevated
in all patients, ranging from 27 to 150U/L in patients with
primary amenorrhea and from 32 to 158U/L in patients with
secondary amenorrhea. Mutations in FSHR, NR5A1, BMP15,
and GDF9, premutations in FMR1, and thyroid, adrenal,
or ovarian autoimmune disorders had been excluded in all
patients. Ethnically and age-matched (23 to 39 years old)
women with normal menarche and menstrual cycles were
invited to participate as controls. Institutional review board
approval and written informed consent were obtained from
all subjects before sample collection for DNA analysis.
2.2. Mutational Analysis of NANOS3. Two protein-coding
transcripts of Nanos3 are described in the Ensembl database:
a 581 bp transcript (ENST00000339133) resulting in a 192-
residue protein and a 776 bp transcript (ENST00000397555)
resulting in a 173-residue protein; only transcript
ENST00000339133 is part of the human consensus coding
sequence set (CCDS).
Following genomic DNA extraction from peripheral
blood leukocytes, the entire exonic region and at least 15 bp
of exon/intron boundaries of transcript ENST00000339133
(RefSeq NM 001098622.2) were PCR-amplified and submit-
ted to direct automated sequencing in an ABI PRISM 310
(Applied Biosystems, Foster City, CA).
2.3. Apoptosis Detection by Flow Cytometry. A pCMV6-
AC-GFP-NANOS3 expression vector (OriGene Technolo-
gies, Rockville, MD) was used as a template to generate a
c.358G>Amutant using the QuikChange site-directed muta-
genesis kit (Stratagene, La Jolla, CA) and specific primers
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(a)
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2nd C2HC motif
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p.Glu120Lys (p.E120K)
D. melanogaster
Macaca mulatta
Homo sapiens
Pan troglodytes
Bos taurus
Rattus norvegicus
Mus musculus
(b)
Figure 1: AMutational analysis ofNANOS3 revealed a homozygous c.358G>A substitution in exon 1 in two sisters with primary amenorrhea.
The GAG to AAG change in codon 120 results in a substitution from glutamic acid to lysine in the codified protein (p.Glu120Lys). B, Cartoon
representation of the NANOS3 protein (192 amino acids), with the zinc finger domain (amino acid 76 to 130) depicted in yellow, showing the
location of the p.Glu120Lys mutation. Glutamic acid 120 (shown as E120) is localized within one of two highly conserved Cys-Cys-His-Cys
(C2HC) motifs (shaded red and yellow boxes). Conservation among species of the second C2HCmotif sequence (human residues 112 to 128)
is shown in detail; glutamic acid 120 (E) is highly conserved. Alignment was performed in Clustal Omega using protein sequences obtained
from UniProt.
(F: 5󸀠 GGC GCC ACA CGT AAG CGC GCC CAC AC
3󸀠; R: 5󸀠 GTG TGG GCG CGC TTA CGT GTG GCG
CC 3󸀠). African green monkey kidney COS-1 cells were
transiently transfected using Lipofectamine 2000 (Invitrogen,
Carlsbad, CA) and analyzed 48 hours later with or without
treatment with 5mM sodium butyrate (Calbiochem, San
Diego, CA). Cells were stained with Annexin-V conjugates
(Molecular Probes Invitrogen, Carlsbad, CA) according to
manufacturer’s protocol. GFP and Annexin-V fluorescence
were excited at 488 nm and 650 nm and emission measured
using 530/30 nm and 660/30 band pass filters, respectively.
2.4. Confocal Microscopy. Confocal microscopymicrographs
were obtained using a 488 nm laser line and light emitted
between 500 and 600 nm for GFP detection and a 650 nm
laser line and light emitted between 660 and 700 nm for
red Annexin-V detection. Images were collected on a META
LSM 510 laser scanning confocal microscope equipped with a
63.0 × 1.2Wobjective (Carl Zeiss, Jena, Germany).The same
settings for image acquisition and processing were applied for
all samples to allow comparison of the fluorescence intensities
among different samples.
2.5. Molecular Modeling of NANOS3. A model for mutated
human NANOS3 was built using the resolved structure
of L3MBTL1 (PDB-ID 2RI7) as template since NANOS3
structure has not yet been resolved. In order to find the
best model for NANOS3, a Blast alignment with proteins
available in PDB was performed. Highest homology was
found with the crystal structure of Nanos from zebrafish
(PDB-ID 3ALR) with 58% identity. However, this structure
did not include the region where the p.Glu120Lys mutation
is located. Therefore, we looked for another protein bearing
similarities with NANOS3. Such protein was L3MBTL1.
Its X-ray resolved structure presented the second highest
homology with NANOS3 (33% of identity) and included
the p.Glu120Lys mutant region. Molecular modeling was
performed with the SwissModel web-served program and
images examined and edited using the web-based BlueStar
STING (CNPTIA-Embrapa, Brazil) and PyMOL softwares
(freely available at http://www.pymol.org).
3. Results
3.1. Identification of NANOS3 Mutation. Mutational analysis
of NANOS3 revealed that two sisters carried a homozygous
c.358G>A, p.Glu120Lys mutation (Figure 1), which was not
detected in 113 ethnically matched control women and has
not been reported in the 1000 Genome Project or dbSNP
databases. Their mother was heterozygous and the father’s
DNA was not available for study. In the remaining 83 women
composing our POI cohort, no new variants were identified
in NANOS3. Two previously described SNPs were identified
in our cohort, rs897790 and rs2016163 (Table 1).
The patients carrying the homozygous c.358G>A muta-
tion were from the northeast region of Brazil (Piauı´ State)
and born to nonconsanguineous parents. At 12 and 16 years
old they were evaluated for breast underdevelopment. Both
girls had not reached menarche, and physical examination
revealed Tanner stage I breast development and Tanner stage
III pubic hair. Basal gonadotropin levels were elevated with
predominantly high FSH levels (LH = 63 and 21U/L,
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Table 1: Polymorphic variants in NANOS3 identified in POI patients and controls.
Genotype frequency (%)
Variant dbSNP id Patients with POI Controls
Wild-type Heterozygote Homozygote Wild type Heterozygote Homozygote
c.-23C>T (5󸀠 UTR) rs897790 60 34.1 5.9 72.5 25.7 1.8
c.353A>G (exon 1, synonymous) rs2016163 50.6 40 9.4 70 27.4 2.6
FSH = 150 and 61U/L, resp.). Estradiol levels were within
the prepubertal range in both girls. Measured heights were
145 and 156 cm, and weights were 38 and 46Kg, respectively.
Pelvic ultrasonography showed no masses, and ovaries were
not visualized. Treatment with conjugated estrogens followed
by progesterone replacement resulted in complete breast
development and normal cycling.
Their heterozygous mother has a history of menarche at
16 years old and difficulties to conceive. Her first pregnancy
was at 27 years old after 4 years of attempts to conceive and
her second and last gestation occurred at 30. Menopause
occurred at 51 years of age.
3.2. Increased Apoptosis In Vitro with p.Glu120Lys Mutant
NANOS3. Considering that Nanos3 has been shown to
maintain germ cell development inmodel organisms through
repression of apoptosis [34], in vitro studies were performed
to assess the effects of the p.Glu120Lys substitution on the
apoptotic rate of cultured cells. COS-1 cells were transfected
with GFP-tagged wild-type or mutant NANOS3 and viability
assessed by Annexin-V staining. Flow cytometry analysis
showed that the percentage of Annexin-V stained GFP-
positive cells was significantly higher in cells transfected with
mutant NANOS3 in comparison to wild type, in untreated or
sodium butyrate-treated cells (𝑃 < 0.05) (Figure 2), indicat-
ing that the p.Glu120Lys substitution profoundly impairs cell
viability.
Since NANOS3 has been shown to act in the cell nucleus
[37], studies were performed to investigate whether the
p.Glu120Lys mutation would affect intracellular localization.
Transfected COS-1 cells were analyzed by confocal laser scan-
ning microscopy for cellular localization of GFP-tagged wild
type or mutant NANOS3 and Annexin-V staining (Figure 3).
Nuclear localization was observed in cells transfected with
both wild type and mutant cDNA. However, Annexin-V
staining in the plasma membrane, indicating apoptosis, was
only detected in cells expressing the p.Glu120Lys mutant
NANOS3.
3.3. In SilicoMutant NANOS3Modelling. Glutamic acid120 is
a negatively charged amino acid locatedwithin the zinc finger
domain. This residue is found at the surface of NANOS3
within the second Cys-Cys-His-Cys (C2HC) motif, which
is important for its ability to bind RNA [40]. In general,
substitution of amino acids that share similar hydrogen
binding capabilities and tridimensional requirements such as
glutamic acid and lysine has limited structural consequences.
However, lysine has a positive charge on the aliphatic side
chain that can affect DNA binding activity when inserted
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Figure 2: Detection of apoptosis using flow cytometry and
Annexin-V staining in COS-1 cells transfected with wild type (WT)
or p.Glu120Lys mutant (MUT) NANOS3-GFP, before and after
induction of apoptosis with sodium butyrate (NaBu). Expression
of mutant NANOS3 results in significantly higher apoptosis in
comparison to wild type (𝑃 < 0.05). Error bars represent SEM for
nine replicates; NT: nontransfected control.
into the zinc finger domain. In silico analysis shows that
lysine 120 establishes a new contact with Lys96 and abolishes
the original contact with His123 (Figure 4). Consequently,
these changes could lead to internal contact conformational
modifications resulting in impaired protein function. In
addition, 3D structure indicates that the negatively charged
glutamic acid 120 residue is surrounded by negatively charged
residues (Figure 5). Therefore, the presence of the positively
charged lysine 120 residue in the protein surface might cause
strong electrostatic repulsion among the side chains and lead
to destabilization upon protein-RNA interaction.
4. Discussion
The present study aimed to investigate the contribution of
variants in NANOS3 to human POI. We have identified
a nonsynonymous homozygous NANOS3 mutation in two
sisters with primary amenorrhea.
During development, once germ cells populate the
gonads, they are exposed to several apoptotic waves.
NANOS3 plays an important role in the maintenance and
survival of primordial germ cells and therefore constitutes
an interesting candidate gene for nonsyndromic POI. Indeed,
NANOS3 has been shown to function in germ cell devel-
opment in a breadth of organisms, from flies and worms
through frogs and mammals. In mice, loss of Nanos3 results
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Nanos3-GFP Annexin-V Merge
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Figure 3: Confocal microscopy analysis of apoptosis in COS-1 cells following 48 h induction of apoptosis with sodium butyrate. In cells
transfected with wild type (WT, upper row) or p.Glu120Lys mutant (Mut, lower row) GFP-tagged NANOS3, expression of green NANOS3-
GFP is seen predominantly in the nucleus. Red Annexin-V staining in the cytoplasm and plasma membrane, indicating apoptosis, is seen in
cells expressing p.Glu120Lys mutant NANOS3 but not in those expressing WT NANOS3.
Wild type Mutant
T124
E120
K96
G116
T124
H123
K120
G116
Figure 4: In silico analysis of amino acid interactionmodification shows the different conformation conferred by the p.Glu120Lys substitution.
Glutamic acid 120 (shown as E120) makes a hydrophobic interaction with lysine 96 (K96) and hydrogen bonds with both glycine 116 (G116)
and threonine 124 (T124). The substitution to lysine 120 (K120) modifies structural points of contact establishing a new interaction with
histidine 123 (His123) through aromatic stacking and abolishes the hydrophobic interaction with K96.
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H123
H90
R119
K93
R121
R126
E120
H123
H90
R119
K93
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K120
Figure 5: Bulk representation of wild-type NANOS3, with p.Glu120Lys mutant shown in details box. The dashed circle highlights a protein
surface region rich in basic residues, shown in blue. At the center of this region, lies the acidic residue glutamic acid 120 (E120), shown in red.
In the details, substitution by lysine 120 (K120) disturbs the electrostatic interactions among adjacent residues.
in infertility due to apoptosis of migrating PGCs during fetal
life, resulting in atrophic gonads where germ cells are absent
[24, 34]. Furthermore, the contribution of Nanos3 to PGC
maintenance and survival seems to be dosage-dependent in
mice, as a model with attenuated Nanos3 transcript levels
displayed markedly reduced numbers of PGCs [39].
In humans, NANOS3 is expressed in fetal and adult
ovaries during multiple stages of oogenesis and in vitro stud-
ies of human embryonic stem cell-derived germ cells have
shown coexpression of NANOS3 in nuclei with important
germ cell factors such as BLIMP1, VASA, and STELLA in
the cytoplasm [37]. In these cells, reduction of NANOS3
expression resulted in altered gene expression patterns and
reduced number of cells in active division, suggesting that
in humans too NANOS3 has an important function in
germ cell maintenance and survival. Recently, a heterozygous
p.Arg153Trp NANOS3 mutation was reported in a 23-year-
old Chinese woman out of a cohort of 100 women with
POI [39]. Familial segregation was not defined, but the
mutation was not found in 200 ethnically-matched controls.
In vitro studies suggested decreased protein stability due to
the p.Arg153>Trp mutation, leading the authors to postulate
amechanismof reduced dosage ofNANOS3 expression in the
ovaries leading to decreased PGC population and resulting in
POI [39].
The p.Glu120Lys mutation identified in our patients lies
within the NANOS3 zinc finger domain, which is composed
of two C2HCmotifs located between amino acids 77 and 131.
The differences in chemical properties between amino acids
might lead to impaired binding of NANOS3 to its mRNA
targets, as suggested by protein modeling. In vitro experi-
ments show that the mutant NANOS3 identified in the two
sisters with POI was associated with increased apoptosis in
transfected cells, suggesting that loss of NANOS3-mediated
protective effect against apoptosis in primordial germ cells
may be the mechanism underlying POI in these patients.
Primordial germ cell pool size in the developing ovary
and maintenance of these cells throughout life are at the cen-
ter of the pathogenesis of POI. It is remarkable that our two
patients with homozygousNANOS3mutation have presented
with primary amenorrhea, perhaps indicating more severely
PGC-depleted ovaries, while their heterozygous mother had
difficulty to conceive, which could represent a manifestation
of insufficient PGC pool size. Indeed, the patient described
by Wu et al. carried a heterozygous missense change and
presented with secondary, rather than primary, amenorrhea
[39], supporting the concept of a dosage effect for NANOS3-
related POI.
In conclusion, we report a rare homozygous missense
mutation in NANOS3 in two Brazilian sisters with primary
amenorrhea from a cohort of 85 Brazilian women with
POI. In vitro and in silico functional studies support that
this inactivating mutation abolishes NANOS3 ability to pre-
vent apoptosis, suggesting a mechanism for POI involving
increased PGC apoptosis during embryonic cell migration.
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